Octapharma Group delivers strong growth in sales and operating income in 2022
The Octapharma Group once again delivered strong results in a challenging environment in 2022, with record sales, operating profit, profit before tax and net profit. Sales increased by 13.7% to €2.854 billion, compared with the previous year, and the company generated an operating income of €522 million.
Commenting on the Group’s results, Octapharma CEO and Chairman Wolfgang Marguerre said: “Overall, we achieved good results last year. I would like to thank all Octapharma employees whose hard work and commitment have made these strong results possible and also the many healthcare professionals and patients around the world who continue to put their faith in us.”
In 2022, we made excellent progress in several of our clinical trials. We successfully completed our LEX-209 phase III study into the efficacy and safety of octaplex®, our four-factor prothrombin complex concentrate, compared to a rival product in treating patients receiving vitamin K antagonist anticoagulant therapy who need urgent surgery with significant bleeding risk. We are hoping to receive FDA approval for octaplex® in the USA during 2023.
The first patients have also been treated in our LEX-210 study investigating the efficacy and safety of octaplex® in the treatment of major bleeding related to direct oral anticoagulant (DOAC) therapy.
The first patients were also treated in our ATN-106 study, a phase III study assessing the efficacy, safety and pharmacokinetics of atenativ®, our human antithrombin III concentrate, in patients with congenital antithrombin deficiency undergoing surgery or delivery.
We have also just received the approval in Europe of octaplasLG® powder and solvent for solution for infusion, the line extension of our long-established octaplasLG®. This new lyophilised presentation maintains the efficacy and safety of the frozen format – however, due to its dried form, it can be stored at room temperature (below 25°C), representing a life-saving treatment option in both civilian and military pre-hospital emergency settings, and in locations with limited frozen storage facilities and cold chain infrastructure needed for fresh-frozen plasma (FFP).
Gross profit in 2022 was €933 million, up 15.5% from the prior year and gross margin increased by 0.5 percentage points to 32.7%. Operating expenses for the year increased to €412 million from €349 million in 2021. Income before tax was a record €503 million and net income a record €448 million, up from €438 million in 2021. Net cash from operating activities was €324 million. Our capital position remains extremely strong, with an equity ratio of 80.1%.
“This strong result was made possible by the continuing engagement and commitment of Octapharma employees around the globe, who have worked tirelessly to increase plasma collection, drive production, ensure the safe and timely delivery of our products, and engage with our customers and patients around the world. Their dedication has positioned our company strongly for future growth,” said Roger Mächler, Chief Financial Officer of the Octapharma Group.
The Annual Report 2022 provides a comprehensive overview of the Octapharma Group, including details of corporate governance and the financial results. Download the full Octapharma 2022 Annual Report here.
Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines.
Octapharma employs more than 11,000 people worldwide to support the treatment of patients in 118 countries with products across three therapeutic areas: Immunotherapy, Haematology, and Critical Care.
Octapharma has seven R&D sites and five state-of-the-art manufacturing facilities in Austria, France, Germany and Sweden, and operates more than 190 plasma donation centres across Europe and the US.